Research & Development at Novartis The Novartis Pharmaceuticals clinical pipeline holds a broad stream of 140 future projects including both new molecular entities and additional indications or formulations for marketed products. Our pipeline has consistently being ranked by experts as one of the strongest in the industry. Our scientists focus on diseases for which medical need remains unmet and strive to improve the drug discovery process with an approach that integrates novel concepts and tools across multiple disease areas.
HARMONIA seeks to identify the best therapeutic option between Kisqali and Ibrance for patients with aggressive HER2-enriched intrinsic subtype of HR+/HER2- advanced breast cancer (ABC) HARMONIA is intended to test whether Kisqali changes tumor biology to enable a better response to endocrine-based therapy even within the more aggressive subtype
PROS is a spectrum of rare disorders caused by PIK3CA mutations and is characterized by atypical, visible overgrowths and anomalies in blood vessels, the lymphatic system and other tissues At 24 weeks, 38% of patients achieved = 20% reduction in the volume of the PROS lesions assessed in the primary endpoint analysis; no patients experienced dis
Biologics License Application (BLA) submission supported by Phase III RATIONALE 302 trial, which met primary endpoint of improvement in overall survival (OS) in people with advanced or metastatic esophageal squamous cell carcinoma (ESCC) who had received prior systemic therapy 1 ESCC is most common type of esophageal cancer globally and sixth le
Novartis will present 12 abstracts at the European Respiratory Society (ERS) International Congress 2021 for Enerzair Breezhaler (IND/GLY/MF*) and Atectura Breezhaler (IND/MF**) - for patients whose asthma is uncontrolled with LABA/ICS^ and ICS, respectively 1,2 Data from post hoc analyses of the Phase III PLATINUM program (including IRIDIUM and
Separate post hoc analyses of pooled Phase III ORION-9, -10 and -11 data show twice-yearly** Leqvio (inclisiran) consistently reduced low-density lipoprotein cholesterol (LDL-C) in patients with atherosclerotic cardiovascular disease (ASCVD) with established cerebrovascular disease (CeVD) 1 and polyvascular disease (PVD) 2 Overall, Leqvio was we
With the MONALEESA-2 final analysis, only Kisqali has reported statistically significant overall survival (OS) benefit with an aromatase inhibitor for postmenopausal women with HR+/HER2- advanced breast cancer in the first-line (1L) setting 2 Kisqali plus letrozole achieved median OS of over five years (63.9 months), a survival benefit of over 12 months vs.
New quality of life data for 177 Lu-PSMA-617 plus standard of care shows delay in worsening of health-related quality of life (HRQoL) and pain in heavily pre-treated patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) compared to standard of care alone1 - US Food and Drug Administration (FDA) granted Breakthroug
Sandoz enters into commercialization agreement for biosimilar bevacizumab with Bio-Thera Solutions, Ltd.
Agreement follows positive NICE recommendation and commits to deliver Leqvio (inclisiran) access via a population health management approach identifying eligible patients across England 1 Over three years ~300,000 patients at high risk of a second cardiovascular event are expected to be treated with inclisiran, a small interfering RNA therapy administered as a 6-monthly maintenance dose ?
New Kisqali (ribociclib)* overall survival (OS) results from MONALEESA-2 trial in HR+/HER2- advanced breast cancer patients in the first-line setting Health-related quality of life, pain and safety outcomes from phase III VISION trial of investigational radioligand therapy 177 Lu-PSMA-617 in patients with metastatic castration-resistant prostate